Sequesta™
Multiple Myeloma
Pre-clinicalActive
Key Facts
About ID4Pharma
ID4Pharma is a private, preclinical-stage biotech developing first-in-class, p62/SQSTM1-targeted small molecule therapies for multiple myeloma. Its lead asset, Sequesta™, has completed FDA IND-enabling studies, demonstrating high efficacy and a favorable safety profile in preclinical models, and is now advancing toward human clinical trials. The company, led by a team with deep pharmaceutical industry and FDA experience, has been awarded a $2.3 million SBIR Fast Track grant and is actively seeking strategic partnerships and investment to fund Phase IB/IIA trials.
View full company profileTherapeutic Areas
Other Multiple Myeloma Drugs
| Drug | Company | Phase |
|---|---|---|
| PRG1801 (Anti-BCMA CAR-T) | Pregene Biopharma | Phase 1 |
| CAR-NK Therapy | Pregene Biopharma | Phase 1 |
| Tasquinimod | Active Biotech | Preclinical |
| BCMA CAR-T | Simnova Biotherapeutics | Phase 1 |
| BCMA panCAR (via Orna partnership) | Simnova Biotherapeutics | Preclinical |
| Measovir®-based candidate | Oncovita | Pre-clinical |
| Kyprolis® (carfilzomib) | Cleo Life Sciences | Approved |
| inobrodib (CCS1477) | CellCentric | Phase 1/2 |
| ISB 2001 | Ichnos Glenmark Innovation | Phase 1b |
| In Vivo Cell Therapy | GigaMune | Pre-clinical |
| Hemady | Dexcel Pharma USA | Approved |
| AV-353 | AVEO Oncology | Pre-clinical |